Microperimetry and Optical Coherence Tomography Changes in Type-1 Diabetes Mellitus without Retinopathy

Background: We aimed to measure and correlate inner retinal layer (IRL) thickness and macular sensitivity by optical coherence tomography (OCT) and by microperimetry, respectively, in type 1 diabetes mellitus patients (DM1) without diabetic retinopathy (DR). Methods: Fifty-one DM1 patients and 81 age-matched healthy subjects underwent measurement of the axial length (AL), retinal thickness in the macular ETDRS areas by swept source (SS)-OCT and macular sensitivity by microperimeter. Results: The total retinal and IRL thicknesses were thicker in the DM1 group (p < 0.05) in practically all ETDRS areas, and they had a generalized decrease in sensitivity (p < 0.05) in 9 areas between both groups. There was a significant negative correlation between retinal sensitivity and age in all areas and in visual acuity (VA) in 5 out of the 9 areas for DM1 patients. Only a mild negative correlation was observed between retinal sensitivity in the 5 degrees nasal inner (5NI) area and in IRL thickness in the temporal inner (TI) area (-0.309 with p = 0.029) in the DM1 group. Conclusion: Aging and disease evolution in DM1 patients without DR signs generate a decrease in retinal sensitivity. There was a direct relationship between retinal sensitivity and macular thickness in the DM1 group

Understanding hydrodechlorination of chloromethanes. Past and future of the technology

Chloromethanes are a group of volatile organic compounds that are harmful to the environment and human health. Abundant studies have verified that hydrodechlorination might be an effective treatment to remove these chlorinated pollutants. The most outstanding advantages of this technique are the moderate operating conditions used and the possibility of obtaining less hazardous valuable products. This review presents a global analysis of experimental and theoretical studies regarding the hydrodechlorination of chloromethanes. The catalysts used and their synthesis methods are summarized. Their physicochemical properties are analyzed in order to deeply understand their influence on the catalytic performance. Moreover, the main causes of the catalyst deactivation are explained, and prevention and regeneration methods are suggested. The reaction systems used and the effect of the operating conditions on the catalytic activity are also analyzed. Besides, the mechanisms and kinetics of the process at the atomic level are reviewed. Finally, a new perspective for the upgrading of chloromethanes, via hydrodechlorination, to valuable hydrocarbons for industry, such as light olefins, is discussedThe authors gratefully acknowledge financial support through research projects SI1/PJI/2019-00487 (Comunidad de Madrid/UAM) and CTM2017-85498-R (FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación). M. Martín Martínez acknowledges a postdoctoral grant, 2017-T2/AMB-5668, from the Comunidad de Madrid “Atracción de talento investigador” programme. S. Liu acknowledges MINECO for his research grant PRE2018-08442

Sistema de b-learning en Farmacología (I): pilotando

Siguiendo el espíritu renovador derivado de la implementación del Espacio Europeo de Educación Superior y utilizando el entorno del Campus Virtual de la UCM (WebCT), se han desarrollado las bases para la implantación de un sistema de b-learning. Los estudiantes de “Farmacología, Farmacia y Terapéutica” de la Licenciatura de Veterinaria podrán consultar, organizado por módulos temáticos, material didáctico para aprender de forma activa los contenidos de esta asignatura troncal. Las herramientas que conforman este sistema presentan diversas finalidades y formatos: formativas (guiones, presentaciones, vídeos, problemas); comunicativas (foro de intercambio de ideas, dudas e iniciativas y avisos); y evaluadoras (autoevaluaciones para los alumnos y encuestas sobre la utilidad de la propia herramienta). La idea es que los estudiantes sean los gestores de su propio aprendizaje. Para ello, cuentan con el apoyo de una herramienta virtual (Aula Virtual de Farmacología), con actividades docentes presenciales (seminarios y tutorías) y con herramientas de evaluación de los conocimientos adquiridos.Following the innovative spirit derived from implementation of the European Higher Education Area and using an online learning environment (Campus Virtual-UCM), the bases for the implantation of a b-learning system have been developed. The students of "Pharmacology, Pharmacy and Therapeutic" of the Veterinary Medicine degree will be able to consult, organized by thematic modules, educational material to learn in an active way the contents of this core subject. The tools that shape this system present diverse purposes and formats: formatives (scripts, presentations, videos, problems); communicatives (forum to exchanging of ideas, doubts or initiatives and notices); assessments (autoevaluations for the pupils and surveys on the usefulness of the own tool). The idea is that students are the managers of their own learning. For it, they have the support of a virtual tool (Virtual Classroom of Pharmacology), face-to-face educational activities (seminars, tutorials) and tools of evaluation of the acquired knowledge

Antimicrobial Peptides Pom-1 and Pom-2 from Pomacea poeyana Are Active against Candida auris, C. parapsilosis and C. albicans Biofilms

Recently two peptides isolated from the Cuban freshwater snail Pomacea poeyana (Pilsbry, 1927) were described to have antimicrobial activity against bacterial pathogens. Here we show considerable activities of Pom-1 and Pom-2 to reduce the viability of C. albicans, C. parapsilosis and the less common species C. auris measured as the decrease of metabolic activity in the resazurin reduction assay for planktonic cells. Although these activities were low, Pom-1 and Pom-2 turned out to be highly potent inhibitors of biofilm formation for the three Candida species tested. Whereas Pom-1 was slightly more active against C. albicans and C. parapsilosis as representatives of the more common Candida species Pom-2 showed no preference and was fully active also against biofilms of the more uncommon species C. auris. Pom-1 and Pom-2 may represent promising lead structures for the development of a classical peptide optimization strategy with the realistic aim to further increase antibiofilm properties and other pharmacologic parameters and to generate finally the first antifungal drug with a pronounced dedication against Candida biofilms

Seaweed-derived proteins and peptides: promising marine bioactives

Seaweeds are a typical food of East-Asian cuisine, to which are alleged several beneficial health effects have been attributed. Their availability and their nutritional and chemical composition have favored the increase in its consumption worldwide, as well as a focus of research due to their bioactive properties. In this regard, seaweed proteins are nutritionally valuable and comprise several specific enzymes, glycoproteins, cell wall-attached proteins, red algae phycobiliproteins, lectins, peptides, or mycosporine-like amino acids. This great extent of molecules has been reported to exert significant antioxidant, antimicrobial, anti-inflammatory, antihypertensive, antidiabetic, or antitumoral properties. Hence, knowledge on algae proteins and derived compounds have gained special interest for the potential nutraceutical, cosmetic or pharmaceutical industries based on these bioactivities. Although several molecular mechanisms of action on how these proteins and peptides exert biological activities have been described, many gaps in knowledge still need to be filled. Updating the current knowledge related to seaweed proteins and peptides is of interest to further asses their potential health benefits. This review addresses the characteristics of seaweed protein and protein-derived molecules, their natural occurrence, their studied bioactive properties, and their described potential mechanisms of action.The research leading to these results was supported by MICINN supporting the Ramón y Cajal grant for M.A. Prieto (RYC-2017-22891), to Xunta de Galicia for the pre-doctoral grant of P. Garcia-Oliveira (ED481A-2019/295), the program Grupos de Referencia Competitiva (GRUPO AA1-GRC 2018) that supports the work of J. Echave, to the Bio Based Industries Joint Undertaking (JU) under grant agreement No 888003 UP4HEALTH Project (H2020-BBI-JTI-2019) that supports the work of P. Otero. The JU receives support from the European Union’s Horizon 2020 research and innovation program and the Bio Based Industries Consortium. P.E.S. Munekata, M. Pateriro, and J.M. Lorenzo acknowledge GAIN (Axencia Galega de Innovación) for supporting this study (grant number IN607A2019/01).info:eu-repo/semantics/publishedVersio

Single-institution experience in clinical trials during the COVID-19 pandemic in Spain: Not so bad after all?

The impact of the COVID-19 outbreak in Spain during March-April 2020 has been unbalanced throughout the different regions of the country. The alarm status defined by the government on March 14, and still in place at the time of this writing, has transformed the country in different perspectives, including care of patients with cancer.1 In many centers, clinical trial activity was suspended, because it was not considered a priority under the health care challenge of the COVID-19 pandemic.2 Nevertheless, experimental therapy is the only and/or best therapeutic option for many patients with cancer

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16 mg/kg) was administered to 73 patients who had >= 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The median duration of daratumumab treatment was 3.3 (range: 0.03-13.17) months, with a median number of 12 (range: 1-25) infusions. Grade 3/4 treatment-emergent adverse events were reported in 74% of patients and included lymphopenia (28.8%), thrombocytopenia (27.4%), neutropenia (21.9%), leukopenia (19.2%), and anemia (15.1%). Common (>5%) serious treatmentemergent adverse events included respiratory tract infection (9.6%), general physical health deterioration (6.8%), and back pain (5.5%). Infusion-related reactions occurred in 45% of patients. The median change from baseline in all domains of the EQ-5D-5L and EORTC QLQ-C30 was mostly 0. A total of 18 (24.7%) patients achieved a partial response or better, with 10 (13.7%) patients achieving a very good partial response or better. Median progression-free survival was 3.98 months. The results of this early access treatment protocol are consistent with previously reported trials of daratumumab monotherapy and confirm its safety and antitumoral efficacy in Spanish patients with heavily treated relapsed or refractory multiple myeloma

Medical geography in the study of hepatitis A, in the Coffee-triangle region, Colombia, 2007-2011

Objectives: There are few studies of geographical characterization of viral hepatitis. For this reason, we after estimating the incidence rates for Hepatitis A (HAV), we developed epidemiological GIS-based maps for this viral disease, within a well-defined geographic region (the coffee triangle) in Colombia. Study design: A retrospective cross-sectional analysis of surveillance data and GIS-based developing of epidemiological maps. Methods: Surveillance cases data (2007-2011) were used to estimate annual incidence rates using reference population data, on hepatitis, to develop the first maps of HAV in the 53 municipalities of the coffee-triangle region of Colombia (departments Caldas, Quindio, Risaralda). GIS used was Kosmo® 3.1. To summarize and compare the data among municipalities and departments (as units of analysis) we generate indicators such as accumulated incidence rates (AIR) and incidence rates ratios. Results: 1518 HAV cases were reported, 47% from Quindío, 30% Caldas and 22% Risaralda. Quindio presented with the highest AIR (131.54) among all the administrative units under study (Caldas, AIR: 46.39; Risaralda, AIR: 37.62). Interestingly, the highest rates in Quindio, during the period, could be related to the increased number of cases reported in two municipalities from 2008 (Quimbaya, AIR ratio: 4.0 and Montenegro: 3.61). The causes that underlie this augmentation will be subject to further research. Conclusions: Incidence rates for HAV is still high in the region. Showing epidemiological data, particularly in maps would allow planning actions oriented to interventions at the different forms of transmission that this disease has, which is highly important for decisions in public health policies

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML